A Novel,Versatile Valved Holding Chamber for Delivering Inhaled Medications to Neonates and Small Children: Laboratory Simulation of Delivery Options

Abstract

BACKGROUND:

Delivery of bronchodilator to infants and small children from a pressurized metered-dose inhaler with valved holding chamber (pMDI-VHC) is limited by airway narrowness, short respiratory cycle time, and small tidal volume (V_T). There is a need for a versatile, efficient VHC, given the variety of treatment modalities.

METHODS:

We tested the AeroChamber Mini VHC (the internal geometry of which is optimized for aerosol delivery, and which accepts a pMDI canister that has a dose counter) in experiments to determine differences in the delivery of hydrofluoroalkane-propelled albuterol (90 μg/actuation) during: mechanical ventilation via endotracheal tube (ETT); manual resuscitation via ETT; and spontaneous breathing via face mask. We tested 5 units of the AeroChamber Mini VHC per test. We simulated the tidal breathing of a premature neonate (V_T 6 mL), a term neonate (V_T 20 mL), and a child approximately 2 years old (V_T 60 mL). We collected the aerosol on an electret filter and quantitatively assayed for albuterol.

RESULTS:

The total emitted mass of albuterol per actuation that exited the VHC was marginally greater during spontaneous breathing (12.1 ± 1.8 μg) than during manual resuscitation (10.0 ± 1.1 μg) (P = .046). Albuterol delivery via mechanical ventilation, though comparable with the premature-neonate model (3.3 ± 1.2 μg), the term-neonate model (3.8 ± 2.1 μg), and the 2-y-old-child model (4.2 ± 2.3 μg) (P = .63), was significantly lower than in the spontaneous-breathing and manual-resuscitation models (P < .001). In the neonatal models the total emitted mass was similar with the spontaneous-breathing model (6.0 ± 1.0 μg with the premature-neonate model, 10.5 ± 0.7 μg with the term-neonate model) and the manual-resuscitation model (5.5 ± 0.3 μg premature-neonate model, 10.7 ± 0.9 μg term-neonate model) (P ≥ .46 via one-way analysis of variance).

CONCLUSION:

The reduced delivery of albuterol during mechanical ventilation (compared to during spontaneous breathing and manual resuscitation via ETT) was probably associated with the saturated atmosphere in the breathing circuit (37°C, relative humidity > 99%), compared to the ambient air (22 ± 1°C, 44 ± 7% relative humidity). The AeroChamber Mini VHC may provide a versatile alternative to VHCs that are designed exclusively for one aerosol treatment modality.

Keywords

neonate small child inhaler aerosol mechanical ventilation manual resuscitation spontaneous breathing simulation

Get full access to this article

View all access options for this article.

References

Hintz

. Pharmacology review: bronchodilator therapy in the preterm infant. Neo Reviews, 2003; 4(9):e245–e249.

American Association for Respiratory Care. AARC Clinical Practice Guideline. Selection of an aerosol delivery device for neonatal and pediatric patients. Respir Care, 1995; 40(12):1325–135.

Ferguson

, Gidwani

. Delivery of bronchodilators in acute asthma in children. Emerg Med. J, 2006; 23(6):471–472.

Stocks

, Hislop

. Structure and function of the respiratory system. In: Bisgaard

, O'Callaghan

, Smaldone

, editors. Drug delivery to the lung. New York: Marcel Dekker; 2002:47–104.

Fink

. Aerosol delivery to ventilated infant and pediatric patients. Respir Care, 2004; 49(6):653–665.

Silverman

. Aerosol therapy in the newborn. Arch Dis Child, 1990; 65(8):906–908.

Schleufe

, Reiffen

, Piepenbrock

. Effective application of bronchodilator aerosols from metered-dose inhalers (MDI) via resuscitator-bag and adapter. Resuscitation, 1998; 39(3):175–178.

Fink

, Dhand

. Bronchodilator resuscitation in the emergency department. Part 1 of 2: device selection. Respir Care, 1999; 44(11):1353–1374.

Waugh

, Deshpande

, Hardwood

. Rapid interpretation of ventilator waveforms. Upper Saddle River, New Jersey: Prentice Hall; 1999.

10.

Bhutani

, Sivieri

. Pulmonary function and graphics. In: Goldsmith

, Karotkin

, editors. Assisted ventilation of the neonate. Philadelphia: WB Saunders; 2004:293–310.

11.

Lough

. Pulmonary function. In: Chatburn

, Lough

, editors. Handbook of respiratory care. Chicago: Year Book Medical Publishers; 1990:41–57.

12.

Mitchell

, Wiersema

, MacKay

, Nagel

, Pischel

, Cripps

. Novel approach for evaluating medication delivered via valved holding chambers (VHCs) with facemask using a face model for infants and small children. In: Dalby

, Byron

, Peart

, Suman

, Farr

, Young

, editors. Respiratory drug delivery. River Grove, IL: Davis Healthcare International; 2008:785–788.

13.

Cripps

, Davis

, Pischel

, Wiersema

, Nagel

, Mitchell

. In-vitro performance of albuterol hfa formulation in two valved holding chambers at low inspiratory flow rates and extended delay times (abstract). J Allergy Clin Immunol, 2008; 121(2 Suppl 1):S9.

14.

Cole

, Mitchell

, Foley

, Nagel

. Hydrofluoroalkane- versus chlorofluorocarbon-beclomethasone delivery in neonatal models. Arch Dis Child Fetal Neonat Edn, 2004; 89(5):F417–F418.

15.

Tal

, Golan

, Grauer

, Aviram

, Albin

, Quastel

. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr, 1996; 128(4):479–484.

16.

GlaxoSmithKline. Ventolin-HFA: prescribing information. Research Triangle Park, NC; 2008. http://us.gsk.com/products/assets/us_ventolin_hfa.pdf. Accessed February 3, 2010.

17.

Fink

, Dhand

, Grychowski

, Fahey

, Tobin

. Reconciling in-vitro and in-vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation, and defining efficiency enhancing factors. Am J Respir Crit Care Med, 1999(1);159:63–68.

18.

Dhand

, Tobin

. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med, 1997; 156(1):3–10.

19.

Miller

, Amin

, Palmer

, Shah

, Smaldone

. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med, 2003; 168(10):1205–1209.

20.

Dhand

, Mercier

. Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv, 2007; 4(1):47–61.

21.

Dhand

. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulmon Deliv, 2008; 21(1):45–60.

22.

Newman

. Therapeutic aerosols 1. Physical and practical considerations. Thorax, 1983; 38(12):881–886.

23.

Cole

. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care, 2000; 45(6):646–651.

24.

Mitchell

, Nagel

. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med, 2003; 16(4):341–377.

25.

Bonam

, Christopher

, Cipolla

, Donovan

, Goodwin

, Holmes

, et al. Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech, 2008; 9(2):404–413.

26.

Bisgaard

. Delivery of inhaled medications in children. J Asthma, 1997; 34(6):443–467.

27.

Esposito-Festen

, Ates

, Van Vliet

FLM

, Verbraak

AFM

, de Jongste

, Tiddens

. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med, 2004; 17(1):1–6.

28.

Shah

, Berlinski

, Rubin

. Force-dependent static dead space of face masks used with holding chambers. Respir Care, 2006; 51(2):140–144.